Co-Presentation of Lupus Nephritis with Autoimmune Hepatitis.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
medline:
31
8
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
BACKGROUND Systemic lupus erythematosus (SLE) is a multiorgan immunologic disease which commonly results in systemic manifestations by involving joints, kidneys, skin, heart, hematologic cell lines, pulmonary and central nervous systems. The hepatic involvement of lupus is relatively less common, which creates diagnostic challenges, as the clinical presentations of lupus hepatitis and autoimmune hepatitis (AIH) are similar. CASE REPORT A 51-year-old woman presented for multiple joint pain that began 2 years ago. Her work-up, including kidney biopsy, was consistent with a diagnosis of class V lupus nephritis. Subsequently, within a few months, she was admitted with acute elevation of liver enzymes and high immunoglobulin IgG level, and a liver biopsy demonstrated impressive interface hepatitis with many plasma cells and lymphocytes, suggestive of chronic hepatitis with high histological activity. This case illustrates the co-presentation of lupus nephritis and AIH, which is a rare association. The patient was managed with a tapering dose of prednisone, hydroxychloroquine initially, and later with mycophenolate mofetil, with complete resolution of liver enzyme abnormalities by 4-month follow-up. CONCLUSIONS Lupus hepatitis is hepatic involvement of SLE, which should be distinguished from AIH. Accurate diagnosis is important, as management and prognosis of these immunologic conditions can differ. Although both entities share clinical and biochemical markers, the presence of anti-ribosomal P antibodies and liver histology features of predominant lymphoid infiltrates with lobular inflammation favor lupus hepatitis. A multidisciplinary approach involving rheumatologists, hepatologists, and pathologists can improve disease outcomes by properly differentiating the 2 entities and guiding the selection of appropriate immunosuppressive therapy.
Identifiants
pubmed: 37641400
pii: 940478
doi: 10.12659/AJCR.940478
pmc: PMC10474845
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e940478Références
Am J Med Sci. 2017 Apr;353(4):329-335
pubmed: 28317620
Gastroenterology. 1993 Dec;105(6):1824-32
pubmed: 8253358
Gastroenterol Hepatol (N Y). 2010 Feb;6(2):108-12
pubmed: 20567552
World J Gastroenterol. 2014 Sep 21;20(35):12662-7
pubmed: 25253972
Ann Rheum Dis. 2021 Jan;80(1):14-25
pubmed: 33051219
Aliment Pharmacol Ther. 2019 Apr;49(7):830-839
pubmed: 30761563
Ann Rheum Dis. 2019 Sep;78(9):1151-1159
pubmed: 31383717
Hepatology. 2009 May;49(5):1782-3; author reply 1783
pubmed: 19402135
J Hepatol. 2011 Mar;54(3):584-5
pubmed: 21159402
Hepatology. 1997 Sep;26(3):567-72
pubmed: 9303484
Hepatology. 2020 Aug;72(2):671-722
pubmed: 31863477
J Gastroenterol Hepatol. 1993 Jan-Feb;8(1):84-8
pubmed: 8439667
N Engl J Med. 2008 Feb 28;358(9):929-39
pubmed: 18305268
Semin Arthritis Rheum. 2006 Jun;35(6):344-8
pubmed: 16765710
World J Gastroenterol. 2007 May 21;13(19):2764-7
pubmed: 17569152
J Hepatol. 1999 Feb;30(2):222-7
pubmed: 10068099
Lancet. 2013 Oct 26;382(9902):1433-44
pubmed: 23768844
Am J Med. 1980 Aug;69(2):187-94
pubmed: 7405944
Hepatol Res. 2007 Sep;37(9):771-4
pubmed: 17506835